Last reviewed · How we verify
Antimalarial monoclonal antibodies
Antimalarial monoclonal antibodies is a Monoclonal antibody Biologic drug developed by Liverpool School of Tropical Medicine. It is currently in Phase 3 development for Malaria prevention and treatment (investigational). Also known as: L9LS.
Monoclonal antibodies that target and neutralize malaria parasites or parasite-derived antigens to prevent infection and reduce disease severity.
Antimalarial monoclonal antibodies are being studied for conditions including malaria, severe malaria, severe anaemia, post-discharge, and systemic lupus erythematosus. The mechanism of action of these antibodies is targeting disialoganglioside GD2, according to ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antimalarial monoclonal antibodies |
|---|---|
| Also known as | L9LS |
| Sponsor | Liverpool School of Tropical Medicine |
| Drug class | Monoclonal antibody |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
These antibodies are designed to bind to specific antigens expressed by Plasmodium parasites or their mosquito vectors, blocking parasite development, transmission, or invasion of host cells. By leveraging the immune system's antibody-mediated mechanisms, they aim to provide protection against malaria infection and reduce transmission potential.
Approved indications
- Malaria prevention and treatment (investigational)
Common side effects
Key clinical trials
- Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
- Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer (PHASE2)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE (PHASE3)
- Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antimalarial monoclonal antibodies CI brief — competitive landscape report
- Antimalarial monoclonal antibodies updates RSS · CI watch RSS
- Liverpool School of Tropical Medicine portfolio CI
Frequently asked questions about Antimalarial monoclonal antibodies
What is Antimalarial monoclonal antibodies?
How does Antimalarial monoclonal antibodies work?
What is Antimalarial monoclonal antibodies used for?
Who makes Antimalarial monoclonal antibodies?
Is Antimalarial monoclonal antibodies also known as anything else?
What drug class is Antimalarial monoclonal antibodies in?
What development phase is Antimalarial monoclonal antibodies in?
Related
- Drug class: All Monoclonal antibody drugs
- Manufacturer: Liverpool School of Tropical Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Malaria prevention and treatment (investigational)
- Also known as: L9LS
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing